BerGenBio
Invention
The pharmaceutical and biotechnology industry is constantly seeking new technologies that improve the drug discovery and development process, and how to reduce the exorbitant cost of this. BerGenBio offers a fully integrated suite of tools to support drug target discovery and development needs. Avaliable proprietary technologies include a unique, patended technology:
CellSelectRNAi™
A technique that allows the RNAi pathay to be reprogrammed to regulate the expression of a gene of interest (target) and act as a surrogate drug.
CellSelectImaging™
A unique biological imaging technology that allows visualization of cells and tissues so that disease development can be followed and drug activity observed.
CellSelectScreening™
A unique battery of biological assay technologies that allows parallel target – compound evaluation.
Applications
BerGenBio offers contract research and development services to the pharmaceutical industry and biotechnology companies and is actively pursuing collaborations for pipeline development of novel drug targets and therapeutics, including small molecules, anti bodies and RNAi drugs.
Advantages
- Significantly reduce the time and cost associated with new drug discovery
– Rapid cell-based identification of functional RNAi effectors not possible by current methods
– Pre clinical data for dose response and side effect profile.
– Increases the efficiency of drug development process
Technology
The development of novel pharmaceutical therapeutics relies on identification of key disease determinants (drug targets).RNAi is now the most important drug target validation approach for the pharmaceutical and biotech industry. BerGenBio have developed an innovative validation and high-throughput discovery technology that effectively addresses major contemporary limitations. This technology builds on validated functional genetic principles and avoids imperfect computer algorithms currently in use. RNAi-based technology allows inactivation of any gene product in any cell.
Interested in this technology? Contact CEO Richard Godfrey, richard.godfrey[at]bergenbio.comClick on the link for more information about the company, or visit BerGenBio website.
